Efficacy and safety of Nintedanib plus Docetaxel in patients with advanced lung adenocarcinoma: complementary and exploratory analyses of the Phase III LUME-Lung 1 Study.
Gottfried, M Bennouna, J Bondarenko, I Douillard, J Heigener, D Krzakowski, M Mellemgaard, A Novello, S Orlov, S Summers, Yvonne J
Gottfried, M
Bennouna, J
Bondarenko, I
Douillard, J
Heigener, D
Krzakowski, M
Mellemgaard, A
Novello, S
Orlov, S
Summers, Yvonne J
Citations
Altmetric:
Abstract
Nintedanib is a triple angiokinase inhibitor approved with docetaxel for adenocarcinoma non-small cell lung cancer after first-line chemotherapy (FLT). In the phase III LUME-Lung 1 study, overall survival (OS) was significantly longer with nintedanib/docetaxel than with placebo/docetaxel in all adenocarcinoma patients and those with time from start of FLT (TSFLT) <9 months.
Description
Date
2017-08
Publisher
Collections
Keywords
Type
Article
Citation
Efficacy and safety of Nintedanib plus Docetaxel in patients with advanced lung adenocarcinoma: complementary and exploratory analyses of the Phase III LUME-Lung 1 Study. 2017, 12 (4):475-485 Target Oncol